Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health. The following experimental protocol was approved by the Animal Care and Use Committee in Showa University.
The experimental protocol was described precisely in a previous report. 13 Each mouse was anesthetized by intraperitoneal injection of 50 mg/kg of pentobarbital diluted in 0.9% sodium chloride solution. Vascular injury was induced by inserting a large wire (0.38 mm in diameter) into the femoral artery. Over the next 5 days, the mice were injected subcutaneously with saline (n=18) or human recombinant G-CSF (Kyowa Hakko Kogyo Co Ltd, Tokyo, Japan) once daily at a dose of 300 g·kg -1 ·day -1 (n=18) or 100 g·kg -1 · day -1 (n=6). The mice injected with 300 g·kg -1 ·day -1 (G-CSF group) were killed by intraperitoneal administration of an overdose of pentobarbital at 1, 3, 7 and 28 days (n=6 in each group). The mice injected with 100 g· kg -1 · day -1 were killed at 7 and 28 days (n=3 in each group), and were used only for morphometric analysis (intima -media ratio and re-endothelialization). At the time of death, each mouse was perfused with 0.9% NaCl solution, followed by perfusion fixation with 4% paraformaldehyde in phosphatebuffered saline (PBS) (pH 7.4). The femoral artery was carefully excised, fixed in 4% paraformaldehyde overnight at 4°C and embedded in paraffin. Cross-sections (5 m) were stained with hematoxylin -eosin.
FACS Analysis
Peripheral blood was collected at 3 and 28 days for white blood cell (WBC) counts and immunofluorocytometric analysis using anti-mouse CD34 (BD Bioscience, San Jose, CA, USA) and Sca-1 (Dainippon Pharma, Osaka, Japan) antibodies. The procedure of immunofluorocytometry was described previously. 14 In brief, a total of 2-3×10 5 cells were resuspended with 200 l of Dulbecco's PBS containing 10% fetal bovine serum and 0.01% NaN3, and incubated for 20 min at 4°C with phycoerhythrin-conjugated monoclonal antibody against CD34 and Sca-1. The immunofluorocytometry was performed with a flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA). All groups were studied in at least triplicate.
TUNEL Analysis
Apoptotic cells were analyzed by the TUNEL method 1 and 7 days after vascular injury. TUNEL assay was performed with an apototosis detection kit (Takara Syuzo, Ohtsu, Japan).
Immunohistochemistry
The Vectastain Elite ABC system (Vector Laboratories, Burlingame, CA, USA) was used for immunohistochemistry. Paraffin-embedded tissue sections were deparaffinized, incubated with 0.3% hydrogen peroxide in methanol for 10 min, blocking with 5% horse serum, and incubated with anti-mouse CD45 antibody (BD Pharmingen 30-F11, Franklin Lakes, NJ, USA), anti-mouse Mac-3 antibody (BioLegend M3/84, San Diego, CA, USA) for inflammatory cells and for 1 h at room temperature in a moisture chamber. After washing and incubating with biotinylated secondary antibodies (1:2,000; Vector Laboratories) for 10 min, the sections were visualized with diamiobenzidine substrate and counterstained with hematoxylin. Negative controls were analyzed using non-immune serum instead of primary antibody. 15 
Immunofluorescent Staining
To clarify which cells express CD34, immunofluorescent double-staining for CD34 antibody and immature smooth muscle cell marker was performed at 1 week, and re-endothelialization was assessed at 4 weeks. Paraffin-embedded tissue sections were deparaffinized, incubated with 0.3% hydrogen peroxide in methanol for 10 min, and blocked with 5% horse serum. Next, the sections were incubated with an anti-mouse CD34 antibody (Santa Cruz, MEC 14.7), -smooth muscle actin ( -SMA) antibody (Dako 1A4, Carpinteria, CA, USA), immature smooth muscle cell marker, MHC-antibody (Covance PRB-445P, Princeton, NJ, USA) or anti-mouse von Willebrand factor (vWF) antibody (Santa Cruz; C-20) for 1 h at room temperature in a moisture chamber. The slides were incubated with each secondary antibody for 90 min with shading from light. FluoroLink Cy3-labeled goat anti-rabbit IgG (red color, Amersham International, Aylesbury, UK; 1:1,000 dilution) was used for as both the anti-CD34 antibody and anti-vWF antibody, and Alexa 488-labeled goat anti-mouse IgG (green color; Molecular Probes, Eugene, Ore., USA; 1:400 dilution) was used as both anti--SMA and anti-MHCantibody. Negative controls were carried out with nonimmune serum instead of primary antibody. The nucleus was stained with DAPI (1:10,000). Sections were observed with a fluorescent light microscope.
Morphometric Analysis
The morphometric analysis of the sections was performed as previously described. 16, 17 Transverse sections were made every 100-m and stained with elastica van Gieson. Five different sections from 6 animals in each group were digitized to trace the lumen, the internal elastic lamina, and external elastic lamina using WIN ROOF image analysis software (Mitani Corporation, Fukui, Japan). The intima -media ratio was averaged for each artery. The ratio of TUNEL-positive cells 1 day after vascular injury was measured by counting the number of neointimal cells with DAPI-stained nuclei. The cells were counted on 5 TUNEL-stained sections visualized under high-power magnification from each of the 6 animals in each group. Endothelialization was morphologically assessed by the immunofluorescent staining with the anti-vWF antibody. Re-endothelialization was calculated as the ratio of the surface covered by vWF-positive cells to the total luminal surface.
The ratio of CD34-positive cells was measured by counting the number of neointimal cells with DAPI-stained nuclei. The number of CD34-positive cells was manually counted in the high-power fields of randomly selected sections. Measurements were taken of 5 sections of the injured arteries from each of the 6 animals in each group.
Preparation and Culture of BMCs
BMCs were aspirated and then cultured in Iscove's modified Dulbecco's medium (DMEM) with 10% fetal bovine serum, penicillin G (100 U/ml), streptomycin (100 g/ml), and amphotericin B (0.2 g/ml). The cells were centrifuged and incubated with 95% air and 5% CO2 at 37°C. Each well contained 1×10 6 cells. After 3 days, at concentrations of 1 and 10 g/ml G-CSF or 10 g/ml platelet-derived growth factor (PDGF) was added to the culture medium. No adherent cells were depleted from the culture solution at any of the medium changes performed every 2-3 days. 18, 19 Immunofluorescence staining was performed using -SMA conjugated Cy-3 (1A4, Sigma, Tokyo, Japan) antibodies and DAPI after 14 days. The number of -SMA (1A4)-positive cells was manually counted in randomly selected highpower fields (×400) using immunostained sections. Ten fields were assessed in each group.
Statistical Analysis
All data are expressed as the mean ± SE. Statistical comparisons were made using the Student's t-test for unpaired samples; p<0.05 was considered statistically significant.
Result

Effect of Vascular Injury and Injection of G-CSF
G-CSF was tolerated by the mice and no abnormal behavior or weight loss was observed. Moreover, there were no differences in the hemodynamics of either group. WBCs were more abundant in the G-CSF group (9,533±167 / l) than in the control group (2,900±33.3 / l, p<0.01) at 3 days after the injury.
FACS Analysis
In the FACS analysis, CD34-/Sca-1-positive progenitor cells were more abundant in the G-CSF group (0.098±0.008) than in the control group (0.051±0.006, p<0.05) at 3 days after the injury (Fig 1) . At 28 days after vascular injury, there was no difference between groups (0.042±0.001 (G-CSF) and 0.041±0.001 (control), p=NS, respectively).
Neointimal Hyperplasia
At 1 week after the injury, neointimal hyperplasia was more evident in the G-CSF group (300 g/kg) (intimamedia ratio 0.375±0.038) than in the control group (intima -media ratio 0.125±0.010, p<0.05) (Figs 2a,b) . However, neointimal hyperplasia was less in the G-CSF group (100 g· kg -1 · day -1 ) (intima -media ratio 0.073±0.004) than in the control group (intima -media ratio 0.125±0.010, p<0.05).
At 4 weeks, neointimal hyperplasia was more evident in the control group (intima -media ratio 2.60±0.066) than in the G-CSF group (intima -media ratio 1.25±0.044, p<0.01) (Figs 3a,b) . Neointimal hyperplasia was more evident in the control group (intima -media ratio 2.60±0.066) than in the G-CSF group (100 g·kg -1 ·day -1 ) (intima -media ratio 1.20±0.066, p<0.01).
TUNEL Analysis
TUNEL analysis revealed apoptotic cells, possibly inflammatory cells, in the G-CSF group, but not appreciably in the control group (Fig 4a) . Morphometric analysis revealed more apoptotic cells in the arterial walls of the G-CSF group (43.4±1.34%) than in the arterial walls of the control group (9.0±0.7%, p<0.01) at 1 day after the injury (Fig 4b) . Apoptotic cells were scarcely observed in either group at 7 days (Fig 4a) .
Immunohistochemistry
At 1 day after the injury, Mac-3-positive inflammatory cell accumulation on the luminal side of the thin neointima was slight in the G-CSF group, but less in the control group (Fig 5) . Neointimal hyperplasia was barely observed in either group.
Taken together with the TUNEL analysis, in the acute phase we observed more apoptotic and inflammatory cells in the injured arteries from the G-CSF group.
Immunofluorescent Staining
At 1 week after the injury, CD45-positive hematopoietic cells were observed in the neointima of both groups. CD34-positive bone-marrow-derived cells were observed in the G-CSF group, but were rarely seen in the control group (11.8±1.40% vs 1.76±0.36%, p<0.05). Some CD34-positive cells were also positive for MHC-, as indicated by immature smooth muscle cell marker. Endothelium was hardly observed in the neointima (Fig 6) . At 4 weeks, re-endothelialization detected by vWF antibody staining was more extensive in the G-CSF group (300 g/kg) (percent luminal coverage 80.6±3.61) than in the control (percent luminal coverage 63.4±3.28, p<0.01). Smooth muscle cells in neo- 
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intima were observed in each group (Figs 7a,b) . Re-endothelialization was also more extensive in the G-CSF group (100 g·kg -1 ·day -1 ) (percent luminal coverage 82.7±3.77) than in the control group (percent luminal coverage 63.4± 3.28, p<0.01).
Culture of BMCs
In the process of cell culture, some adherent cells changed their morphology to that of smooth-muscle-like cells. At 14 days, when compared with the control values, the 1A4-positive smooth muscle cells were significantly more abundant 
Discussion
The present study has demonstrated that G-CSF modulates vascular repair through the mobilization of progenitor cells from the bone marrow into peripheral blood. High doses of G-CSF may induce neointimal vulnerability by mobilizing smooth muscle progenitor cells in the early phase of vascular repair. G-CSF also accelerates re-endothelialization, possibly via mobilization of EPCs and promotion of vascular healing in the later phase after injury. Our in vitro experiments also revealed that G-CSF can modulate the differentiation of mice BMCs into smooth-muscle-like cells.
Kong et al 9 recently demonstrated that daily injection of G-CSF (50 g/kg) for 8 days before vascular injury enhanced the repair of the injured arteries in a mouse model. According to their data, G-CSF stimulated bone marrow and thus increased circulatory EPCs, leading to marked inhibition of neointimal hyperplasia and accelerated re-endothelialization of the injured vessel. In another experiment, Yoshioka et al 11 administered daily injections of 100 g/kg of G-CSF for 4 days before vascular injury and 6 days after vascular injury. The vessels of the experimental animals in their study exhibited decreased neointimal formation and reduced levels of the inflammatory cytokine interleukin-6. Those studies and our present study using daily injections of 100 g/kg of G-CSF for 5 days after vascular injury demonstrate the efficacy of G-CSF administration for vascular repair in vivo. Some reports have indicated that G-CSF modulates vascular repair through bone-marrow-derived c-kit + /Flk-1 + progenitor cells, thus contributing directly to endothelial regeneration via the mechanism of NO-mediated arterial relaxation. 12, 20 In an in-vitro study, G-CSF was shown to confer an anti-apoptotic effect by modulating smooth muscle cells through signal transduction via the Jak/Stat pathway, while simultaneously producing eNOS, 21 an enzyme with beneficial anti-inflammatory effects for the vasculature. Cytotoxic effects of G-CSF have been reported, however. In the MAGIC cell randomized clinical trial, 10 G-CSF therapy with intracoronary infusion was found to aggravate re-stenosis, which indicates that G-CSF may increase not only the EPCs, but also putative smooth muscle progenitor cells. Other groups have reported the unexpected effects of aggravated plaque stability via an accumulation of the inflammatory cells in vivo. 22 In this study we induced a wire injury of the mouse femoral artery and attempted to mobilize more CD34-/Sca-1-positive cells by injecting G-CSF at a dose of 300 g·kg -1 · day -1 , a dose higher than previously reported. 9, 11 Whereas our findings revealed more neointimal hyperplasia in the early phase, some groups have found that G-CSF inhibits neointimal hyperplasia in all phases. 9, 11 Our immunohistologic data demonstrated that neointimal hyperplasia in the early phase comprises many CD34-positive cells, which suggests that the mobilized stem cells affect the process of neointimal formation and increase the intima -media ratio. High-dose G-CSF mobilized more bone marrow stem cells to the peripheral circulation, and the mobilized cells accumulated on the injured side of the vascular lumina. We also found that some of the cells may transdifferentiate into smooth-muscle-like cells, as our immunohistochemistry identified double-positive cells with CD34 and immature smooth muscle cell antibodies in the neointimal portion. Our in-vitro study also revealed that G-CSF modulated the transdifferentiation of BMCs to smooth-muscle-like cells.
In contrast to what we observed in the early phase, in the later phase that the intima -media ratio was smaller in the G-CSF group than in the control group. G-CSF may promote re-endothelialization by mobilizing EPCs after elimination of apoptotic cells and maturation of neointimal hyperplasia. G-CSF is widely known to have pleiotropic effects, such as cytoprotective and anti-apoptotic effects. 9 Some investigators have shown that bone-marrow-derived cells can transdifferentiate into various lineages, particular at the site of injury in the artery, and can transform into progenitors of either smooth muscle cells or endothelial cells. [23] [24] [25] [26] What the bone-marrow-derived cells transform into is related to the conditions at the injured site, such as inflammatory, apoptotic, and some vasoactive factors. 17, 27 It may be that endothelial injury and the subsequent deposition of platelets and inflammatory or apoptotic cells and release of vasoactive factors in the early phase after vascular injury provide optimal conditions for homing and differentiation of circulating smooth muscle progenitors. In the late phase, after the recruitment of inflammatory cells, bone-marrow-derived cells tend to transform into EPCs, which may promote re-endothelialization.
Study Limitation
In the present study we attempted to mobilize more CD34-/Sca-1-positive cells by injecting G-CSF at 300 g· kg -1 ·day -1 , a dose that is higher than previously reported; however, it is not a suitable clinical dose for patients who had atherosclerotic lesions.
Conclusion
High-dose G-CSF induces neointimal proliferation by causing excessive inflammation and BMC mobilization in the early phase after vascular injury. Later, in the advanced phase, it induces early re-endothelialization, resulting in an inhibition of neointimal hyperplasia.
